H.C. Wainwright Reiterates a Buy on BridgeBio Pharma (BBIO)

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the Best Performing Long Term Stocks According to Analysts. On September 15, H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on BridgeBio Pharma, Inc. (NASDAQ:BBIO) with a price target of $70.

The analyst noted that his positive sentiment of the company is based on the company’s lead drug candidate Encaleret, which targets autosomal dominant hypocalcemia type 1 (ADH1). ADH1 is a rare condition with high unmet medical needs and often goes undiagnosed. He highlighted that Encaleret works differently from conventional treatments and acts as a negative allosteric modulator of the calcium-sensing receptor. This mechanism directly addresses the root cause of ADH1, which current therapies do not fully manage.

Moreover, the drug has shown strong results in a Phase 2 trial. Over 42 months, it helped normalize patients’ blood calcium, parathyroid hormone, and urine calcium levels. Importantly, Encaleret demonstrated a durable effect and a good safety profile over this long-term study.

In the United States alone there are around 12,000 patients affected by ADH1, presenting a sizable market opportunity for BridgeBio Pharma, Inc. (NASDAQ:BBIO).

BridgeBio Pharma, Inc. (NASDAQ:BBIO) discovers and develops medicines for genetic diseases. Its drug pipeline includes treatments for amyloidosis, achondroplasia, hypocalcemia, and muscular dystrophy.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.